ClinicalTrials.gg
RecruitingNCT05873023Updated May 24, 2023

Chewing Gum and Cognitive Function

An interventional study of Chewing gum in Cognitive Dysfunction, sponsored by Inha University Hospital. Recruiting at 4 sites in Korea, Republic of. Open to participants aged 60 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Inha University Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Oct 2022, registered May 2023).
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
60 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.

Planned enrollment
29th of 57
94 · median 94
Started
2022
with 8 others
No phase
37 of 74
8 open now
Primary completion
2023-12
later than 3 of 23 live
Registered
53rd of 74
by date
Lead sponsor
6 of 74
Inha University Hospital

Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 29th largest by planned enrollment of the 57 interventional ones that give a count, is one of 9 that started in 2022, is one of 37 with no phase, reaches primary completion later than 3 of the 23 other live ones, and was the 53rd registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 60 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is to investigate whether the improvement or maintenance of cognitive function is superior to the control group when gum chewing is performed in elderly people with subjective cognitive decline or mild cognitive impairment.

Read the detailed description

The intervention group chew one unscented gum provided by the study for 12 weeks. Using KakaoTalk, the coordinator sends a chewing gum alarm.

The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side.

After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting an authentication photo in the KakaoTalk chat room.

The research coordinator checks the certification on a weekly basis and sends a separate phone call to encourage participants who do not chew gum more than twice a week.

03

Conditions studied

  • Cognitive Dysfunction
04

Who can participate

Ages eligible
60 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 60 to 79 years of age
  • All posterior teeth are evenly occluded on both sides, and those who have lost 4 or less teeth in the posterior teeth
  • Those who scored 50 points or less on the periodontal disease self-checklist
  • Meet the diagnostic criteria for subjective cognitive decline or mild cognitive impairment
  • Provide written

Exclusion criteria

Exclusion Criteria:

  • Those who have difficulty in chewing due to toothache, periodontal disease, temporomandibular joint disease, severe malocclusion, shaking teeth, etc.
  • Those who wear dentures on the upper or lower teeth
  • Dementia
  • Major psychiatric illness such as major depressive disorders
  • Other neurodegenerative disease (e.g., Parkinson's disease)
  • Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease, or any medical conditions preventing to complete the study as judged by the study physician
  • Severe loss of vision, hearing, or communicative disability
  • Significant laboratory abnormality that may result in cognitive impairment
  • Any conditions preventing cooperation as judged by the study physician
  • Coincident participation in any other intervention trial
  • Those who are planning dental treatment such as preservation, prosthetics, and implants during the research period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Intervention

    The intervention group chew one unscented gum provided by the study for 12 weeks. The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side. After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting a proof photo in the KakaoTalk chat room.

    Other: Chewing gum

  • No intervention
    Control

    The control group does not participate in chewing gum.

Interventions

  • OtherChewing gum

    chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.

06

What researchers measure

Primary outcomes

  1. Change of cognition

    Repeatable Battery for the Assessment of Neuropsychological Status (range 40-160). Higher scores indicate better performance.

    Time frame: Change from Baseline at 12 weeks

Secondary outcomes

  1. Change of global cognition

    Korean Mini-Mental State Examination-2 (range, 0-30). Higher scores indicate better performance.

    Time frame: Change from Baseline at 12 weeks

  2. Change of function

    Clinical Dementia Rating scale-Sum of Boxes (range 0-18). Higher scores indicate worse performance.

    Time frame: Change from Baseline at 12 weeks

  3. Change of depression

    Geriatric Depression Scale-15 items (range 0-15). Higher scores indicate worse mood.

    Time frame: Change from Baseline at 12 weeks

  4. Change of activities of daily living

    Bayer Activities of Daily Living (range 1-10). Higher scores indicate worse performance.

    Time frame: Change from Baseline at 12 weeks

  5. Change of quality of life

    Quality of life-Alzheimer's disease (range 0-52). Higher scores indicate better performance.

    Time frame: Change from Baseline at 12 weeks

Other outcomes

  1. Change of cortical thickness and brain network function

    brain MRI (3D-T1 weighted images and resting state functional MRI)

    Time frame: Change from Baseline at 12 weeks

07

Study locations

4 of 4 sites recruiting
  • Bobath Memorial Hospital
    Seongnam, Gyeonggi-do 13552, Korea, Republic of
    Recruiting
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
    Recruiting
    • Seong Hye Choi, MD · Contact
  • Ewha Womans Seoul Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Jee Hyang Jeong, MD, PhD · Contact
  • Ajou University Hospital
    Suwon, Korea, Republic of
    Recruiting
    • So Young Moon, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — The data that support the findings of this study will be available from the principal investigator upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data will be available for 2 years since March 2025.

Access criteria: Reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2023, 13 months after the start.

Of 1,450 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 13 months is below that.

Counting every sponsor, half of 1,519 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
May 24, 2023
StartActual
Oct 17, 2022
Primary completionEst.
Dec 15, 2023
CompletionEst.
Dec 29, 2023
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05873023
Lead sponsor
Inha University Hospital
Collaborators
Bobath Memorial Hospital
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Oct 17, 2022
Primary completion
Dec 15, 2023 (estimated)
Completion
Dec 29, 2023 (estimated)
Last update
May 24, 2023

Study contacts

Seong Hye Choi, MD, PhD
Contact
seonghye@inha.ac.kr
82 32 8902947
Hae Ri Na, MD, PhD
Contact
neuna102@paran.com
Hae Ri Na, MD, PhD
principal investigator · Bobath Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion